GSA Capital Partners’s Filana Therapeutics FLNA Stock Holding History

GSA Capital Partners’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$368K	Sell	217,844 -70,035	-24%	-$144K	0.02%	1115
2025 Q4	$570K	Buy	+287,879	New	+$922K	0.05%	723
2024 Q3	–	Sell	-24,753	Closed	-$306K	–	1965
2024 Q2	$306K	Buy	+24,753	New	+$522K	0.02%	1274
2024 Q1	–	Sell	-23,819	Closed	-$536K	–	1928
2023 Q4	$536K	Buy	+23,819	New	+$503K	0.05%	750
2021 Q3	–	Sell	-5,104	Closed	-$436K	–	1728
2021 Q2	$436K	Buy	+5,104	New	+$273K	0.05%	720
2021 Q1	–	Sell	-18,646	Closed	-$127K	–	1443
2020 Q4	$127K	Buy	+18,646	New	+$166K	0.02%	1071
2015 Q2	–	Sell	-15,965	Closed	-$211K	–	2160
2015 Q1	$211K	Sell	15,965 -11,150	-41%	-$150K	0.01%	1905
2014 Q4	$385K	Sell	27,115 -1,943	-7%	-$33.6K	0.03%	1111
2014 Q3	$795K	Buy	29,058 +17,145	+144%	+$521K	0.04%	634
2014 Q2	$480K	Buy	+11,913	New	+$441K	0.02%	1170

Other funds holding FLNA

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

GSA Capital Partners's FLNA Position: Q1 2026 in Review

GSA Capital Partners reduced its Filana Therapeutics (FLNA) stake by 24% in Q1 2026, selling an estimated $144K and leaving 217,844 shares worth $368K. The position accounts for 0.02% of the portfolio, ranked #1115.

GSA Capital Partners first reported a position in FLNA in Q2 2014 and has held it in 10 quarters since. The position peaked at $795K in Q3 2014. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

GSA Capital Partners held 217,844 shares of Filana Therapeutics worth $368K as of Q1 2026.
GSA Capital Partners sold 70,035 Filana Therapeutics shares in Q1 2026, an estimated $144K.
Filana Therapeutics made up 0.02% of GSA Capital Partners's portfolio in Q1 2026, its #1115 holding.
GSA Capital Partners first reported a position in Filana Therapeutics in Q2 2014 and has held it in 10 quarters since.
GSA Capital Partners's Filana Therapeutics position peaked at $795K in Q3 2014.
101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.